TPWA
RCUS icon

Twin Peaks Wealth Advisors’s Arcus Biosciences RCUS Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-166
Closed -$3.59K – 1725
2026
Q1 		$3.59K Buy
+166
New +$3.58K ﹤0.01% 1512

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Twin Peaks Wealth Advisors's RCUS Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Arcus Biosciences (RCUS) in Q2 2026, closing a stake of 166 shares — an estimated $3.59K sold.

Twin Peaks Wealth Advisors first reported a position in RCUS in Q1 2026 and held it in 1 quarter. The position peaked at $3.59K in Q1 2026. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Arcus Biosciences position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 166 Arcus Biosciences shares in Q2 2026, an estimated $3.59K.
  • Twin Peaks Wealth Advisors first reported a position in Arcus Biosciences in Q1 2026 and held it in 1 quarter.
  • Twin Peaks Wealth Advisors's Arcus Biosciences position peaked at $3.59K in Q1 2026.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.